A Comprehensive RNA Study to Identify circRNA and miRNA Biomarkers for Docetaxel Resistance in Breast Cancer.

RNA sequencing breast cancer circRNA docetaxel resistance miRNA

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2021
Historique:
received: 18 02 2021
accepted: 26 04 2021
entrez: 31 5 2021
pubmed: 1 6 2021
medline: 1 6 2021
Statut: epublish

Résumé

To investigate the relationship between non-coding RNAs [especially circular RNAs (circRNAs)] and docetaxel resistance in breast cancer, and to find potential predictive biomarkers for taxane-containing therapies, we have performed transcriptome and microRNA (miRNA) sequencing for two established docetaxel-resistant breast cancer (DRBC) cell lines and their docetaxel-sensitive parental cell lines. Our analyses revealed differences between circRNA signatures in the docetaxel-resistant and -sensitive breast cancer cells, and discovered circRNAs generated by multidrug-resistance genes in taxane-resistant cancer cells. In DRBC cells, circABCB1 was identified and validated as a circRNA that is strongly up-regulated, whereas circEPHA3.1 and circEPHA3.2 are strongly down-regulated. Furthermore, we investigated the potential functions of these circRNAs by bioinformatics analysis, and miRNA analysis was performed to uncover potential interactions between circRNAs and miRNAs. Our data showed that circABCB1, circEPHA3.1 and circEPHA3.2 may sponge up eight significantly differentially expressed miRNAs that are associated with chemotherapy and contribute to docetaxel resistance

Identifiants

pubmed: 34055636
doi: 10.3389/fonc.2021.669270
pmc: PMC8162208
doi:

Types de publication

Journal Article

Langues

eng

Pagination

669270

Informations de copyright

Copyright © 2021 Huang, Li, Mo, Geng, Wen, Zhang, Guo, Wu, Li, Brünner and Stenvang.

Déclaration de conflit d'intérêts

Author PH, FL, ZM, CG, FW, CZ, JG and LL were employed by the company BGI-Shenzhen. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Clin Oncol. 2003 Mar 15;21(6):968-75
pubmed: 12637459
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Lung Cancer. 2014 Sep;85(3):442-8
pubmed: 24997136
J Hematol Oncol. 2016 Aug 12;9(1):69
pubmed: 27516205
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Int J Clin Exp Pathol. 2015 Jul 01;8(7):8348-57
pubmed: 26339404
Oncotarget. 2016 Aug 9;7(32):51773-51783
pubmed: 27429046
Biomed Res Int. 2017;2017:8421614
pubmed: 28656150
Yi Chuan. 2020 Aug 20;42(8):799-809
pubmed: 32952115
Mol Cell. 2014 Oct 2;56(1):55-66
pubmed: 25242144
Cell Death Differ. 2010 Feb;17(2):193-9
pubmed: 19461653
J Transl Med. 2016 Jul 28;14(1):225
pubmed: 27465405
PLoS Biol. 2004 Nov;2(11):e363
pubmed: 15502875
Int J Breast Cancer. 2013;2013:137414
pubmed: 23864953
Nucleic Acids Res. 2016 Feb 18;44(3):1370-83
pubmed: 26657629
Zhonghua Zhong Liu Za Zhi. 2013 May;35(5):325-30
pubmed: 24054006
Breast Cancer Res Treat. 2012 Jan;131(2):445-54
pubmed: 21399894
Int J Oncol. 2010 May;36(5):1235-41
pubmed: 20372798
Am J Cancer Res. 2015 Apr 15;5(5):1741-50
pubmed: 26175942
J Biomed Inform. 2011 Oct;44(5):839-47
pubmed: 21605702
Genome Biol. 2014;15(12):550
pubmed: 25516281
Int J Clin Exp Pathol. 2015 Feb 01;8(2):1515-24
pubmed: 25973036
Nat Commun. 2016 Apr 06;7:11215
pubmed: 27050392
Cell. 2014 Sep 25;159(1):134-147
pubmed: 25242744
Nucleic Acids Res. 2016 Apr 7;44(6):2846-58
pubmed: 26861625
J Biol Chem. 2015 Dec 18;290(51):30342-50
pubmed: 26518874
Cancer Cell. 2013 Feb 11;23(2):238-48
pubmed: 23410976
Curr Cancer Drug Targets. 2003 Jun;3(3):193-203
pubmed: 12769688
Sci Rep. 2018 Dec 19;8(1):17970
pubmed: 30568280
Nat Genet. 2007 Oct;39(10):1278-84
pubmed: 17893677
J Cell Biochem. 2015 Jul;116(7):1341-9
pubmed: 25640606
Tumour Biol. 2015 Jun;36(6):4327-38
pubmed: 25596703
Expert Opin Biol Ther. 2014 Sep;14(9):1285-93
pubmed: 24941322
Cancers (Basel). 2020 Nov 10;12(11):
pubmed: 33182737
J Biotechnol. 2016 Nov 20;238:42-51
pubmed: 27671698
RNA Biol. 2013 Nov;10(11):1700-13
pubmed: 24157646
Oncol Rep. 2013 Nov;30(5):2179-86
pubmed: 23970317
Int J Clin Exp Pathol. 2015 Jun 01;8(6):6847-58
pubmed: 26261572
Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W720-4
pubmed: 16845106
BMC Genomics. 2016 Jun 09;17:442
pubmed: 27277198
Clin Cancer Res. 2014 Dec 1;20(23):6187-99
pubmed: 25294901
Acta Pharmacol Sin. 2016 Apr;37(4):519-29
pubmed: 26924291
Tumour Biol. 2016 Sep;37(9):11959-11971
pubmed: 27101199
Oncotarget. 2015 Mar 20;6(8):6001-13
pubmed: 25749389
Trends Genet. 2016 May;32(5):309-316
pubmed: 27050930
Sci Rep. 2016 Aug 03;6:30919
pubmed: 27484176
Nucleic Acids Res. 2016 Apr 7;44(6):e58
pubmed: 26657634
Oncotarget. 2016 May 3;7(18):26680-91
pubmed: 27058418
J Am Chem Soc. 1971 May 5;93(9):2325-7
pubmed: 5553076
Breast Cancer (Auckl). 2012;6:159-71
pubmed: 23133315
Int J Mol Sci. 2017 Mar 09;18(3):
pubmed: 28282919
Oncotarget. 2016 May 10;7(19):28195-206
pubmed: 27057640
Tumour Biol. 2016 Feb;37(2):2765-71
pubmed: 26408183
Genome Biol. 2013 Apr 25;14(4):R36
pubmed: 23618408
Cancer Lett. 2013 Feb 1;329(1):91-8
pubmed: 23142283
Nature. 2013 Mar 21;495(7441):384-8
pubmed: 23446346
Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W451-4
pubmed: 16845047
Epigenomics. 2017 Sep;9(9):1175-1188
pubmed: 28803498
Yale J Biol Med. 2016 Dec 23;89(4):527-537
pubmed: 28018143
Biochemistry. 1993 Mar 23;32(11):2747-55
pubmed: 8096151
PLoS One. 2015 Mar 04;10(3):e0117994
pubmed: 25738497
Biochem Biophys Res Commun. 2016 Aug 26;477(3):467-72
pubmed: 27318090
Cochrane Database Syst Rev. 2015 Jun 10;(6):CD003366
pubmed: 26058962
Neuropharmacology. 2016 Nov;110(Pt A):362-375
pubmed: 27487563
Mol Biol Rep. 2012 Apr;39(4):3505-16
pubmed: 21720762
J Natl Cancer Inst. 1991 Feb 20;83(4):288-91
pubmed: 1671606
Database (Oxford). 2020 Jan 1;2020:
pubmed: 32705130
Lancet Oncol. 2004 Jun;5(6):372-80
pubmed: 15172358
Sci Rep. 2016 Apr 05;6:23892
pubmed: 27046651
Elife. 2015 Aug 12;4:
pubmed: 26267216
Gene. 2017 Feb 5;600:21-28
pubmed: 27913185

Auteurs

Peide Huang (P)

BGI, BGI-Shenzhen, Shenzhen, China.

Fengyu Li (F)

BGI Genomics, BGI-Shenzhen, Shenzhen, China.

Zongchao Mo (Z)

BGI Genomics, BGI-Shenzhen, Shenzhen, China.

Chunyu Geng (C)

MGI, BGI-Shenzhen, Shenzhen, China.

Fang Wen (F)

MGI, BGI-Shenzhen, Shenzhen, China.

Chunyan Zhang (C)

MGI, BGI-Shenzhen, Shenzhen, China.

Jia Guo (J)

BGI, BGI-Shenzhen, Shenzhen, China.

Song Wu (S)

Shenzhen Luohu Hospital Group, The Affiliated Luohu Hospital of Shenzhen University, Shenzhen, China.

Lin Li (L)

BGI Genomics, BGI-Shenzhen, Shenzhen, China.
National Research Center for Translational Medicine, National Key Scientific Infrastructure for Translational Medicine, Shanghai Jiao Tong University, Shanghai, China.

Nils Brünner (N)

Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Jan Stenvang (J)

Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Classifications MeSH